S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$1.11
-2.6%
$1.22
$0.84
$2.03
$42.32M0.99121,264 shs55,034 shs
CZX
Canada Zinc Metals
C$0.31
+∞
C$0.31
C$0.22
C$0.39
C$51.69MN/A238,645 shs118,500 shs
First Capital Realty Inc. stock logo
FCR
First Capital Realty
C$20.86
C$18.60
C$22.79
N/AN/A468,009 shs3.04 million shs
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
$177.07
$177.00
$103.67
$177.38
$16.26B1.06746,779 shsN/A
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
+2.70%-10.24%-0.87%+1.79%-27.85%
CZX
Canada Zinc Metals
0.00%0.00%0.00%0.00%0.00%
First Capital Realty Inc. stock logo
FCR
First Capital Realty
0.00%0.00%0.00%0.00%0.00%
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
1.3893 of 5 stars
3.50.00.00.00.03.31.3
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/AN/AN/AN/A
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
1.2365 of 5 stars
0.00.00.04.40.01.72.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
3.00
Buy$7.00530.63% Upside
CZX
Canada Zinc Metals
N/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/A
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
N/AN/AN/AN/A

Current Analyst Ratings

Latest VAR, BOLT, CZX, and FCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/22/2024
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$7.88M5.37N/AN/A$2.97 per share0.37
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/AN/A
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
$3.17B5.13$5.07 per share34.94$22.92 per share7.73

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$69.20M-$1.83N/AN/AN/A-878.58%-51.18%-37.81%5/9/2024 (Estimated)
CZX
Canada Zinc Metals
N/AN/A0.00N/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/A0.00N/AN/AN/AN/AN/A5/1/2024 (Confirmed)
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
$269.20M$3.9160.4330.11N/A8.50%18.45%8.08%N/A

Latest VAR, BOLT, CZX, and FCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
C$0.29N/A-C$0.29N/AN/AN/A
3/21/2024Q4 2023
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$0.47-$0.47N/A-$0.47$1.97 million$2.09 million
2/6/2024Q4 2023
First Capital Realty Inc. stock logo
FCR
First Capital Realty
C$0.31C$0.81+C$0.50C$0.81N/AC$171.18 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
N/AN/AN/AN/AN/A
CZX
Canada Zinc Metals
N/AN/AN/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/AN/AN/A
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
N/AN/AN/AN/AN/A

Latest VAR, BOLT, CZX, and FCR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/15/2024
First Capital Realty Inc. stock logo
FCR
First Capital Realty
MonthlyC$0.074.14%4/29/20244/30/20245/15/2024
3/15/2024
First Capital Realty Inc. stock logo
FCR
First Capital Realty
MonthlyC$0.073/27/20243/28/20244/15/2024
2/6/2024
First Capital Realty Inc. stock logo
FCR
First Capital Realty
MonthlyC$0.072/28/20242/29/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
0.15
5.17
5.17
CZX
Canada Zinc Metals
N/AN/AN/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/A
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
N/A
1.40
1.13

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
86.70%
CZX
Canada Zinc Metals
N/A
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/A
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
86.96%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
10038.13 million27.30 millionNot Optionable
CZX
Canada Zinc Metals
147,000166.73 millionN/ANot Optionable
First Capital Realty Inc. stock logo
FCR
First Capital Realty
N/AN/AN/ANot Optionable
Varian Medical Systems, Inc. stock logo
VAR
Varian Medical Systems
10,00091.84 millionN/AOptionable

VAR, BOLT, CZX, and FCR Headlines

SourceHeadline
DelveInsight Business Research, LLP: Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsightDelveInsight Business Research, LLP: Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
finanznachrichten.de - April 18 at 6:35 PM
This device treats overactive bladder without drugs or surgeryThis device treats overactive bladder without drugs or surgery
medicaldesignandoutsourcing.com - April 18 at 6:35 PM
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsightGlobal Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
finance.yahoo.com - April 18 at 6:35 PM
Raigmore Hospital in Scotland selects RayCareRaigmore Hospital in Scotland selects RayCare
finance.yahoo.com - April 17 at 3:14 PM
PH’s 1st dedicated cancer hospital rises in Taguig CityPH’s 1st dedicated cancer hospital rises in Taguig City
msn.com - April 15 at 10:35 PM
Robotic Radiotherapy Market Worth $1.9 billion | MarketsandMarkets™Robotic Radiotherapy Market Worth $1.9 billion | MarketsandMarkets™
finance.yahoo.com - April 15 at 5:35 PM
Robotic Radiotherapy Market Worth $1.9 billion | MarketsandMarketsRobotic Radiotherapy Market Worth $1.9 billion | MarketsandMarkets
finanznachrichten.de - April 15 at 12:34 PM
Ayala cancer hospital ready to serve 10,000 patients this yearAyala cancer hospital ready to serve 10,000 patients this year
msn.com - April 11 at 2:56 PM
Global Superficial Radiation Therapy System Industry is expected to reach US$ 58.2 Million by 2030, With A strong 3.8% CAGR | FMI | FMIGlobal Superficial Radiation Therapy System Industry is expected to reach US$ 58.2 Million by 2030, With A strong 3.8% CAGR | FMI | FMI
fmiblog.com - April 8 at 6:11 PM
Next-generation PARP inhibitor demonstrates clinical benefit in patients with homologous recombination repair-deficient breast cancerNext-generation PARP inhibitor demonstrates clinical benefit in patients with homologous recombination repair-deficient breast cancer
eurekalert.org - April 8 at 1:10 PM
The Lancet: Prostate cancer cases expected to double worldwide between 2020 and 2040, new analysis suggestsThe Lancet: Prostate cancer cases expected to double worldwide between 2020 and 2040, new analysis suggests
eurekalert.org - April 5 at 1:10 AM
Global Brachytherapy Market Set to Skyrocket, Surpassing US$ 2.1 Billion by 2032Global Brachytherapy Market Set to Skyrocket, Surpassing US$ 2.1 Billion by 2032
fmiblog.com - April 4 at 1:43 AM
New method allows miniature robots and surgical instruments to achieve precise localization inside the bodyNew method allows miniature robots and surgical instruments to achieve precise localization inside the body
msn.com - April 2 at 3:39 PM
Global Radiotherapy Device Industry Expects to Reach US$ 12,895.19 Million with 6.6% CAGR by 2033 | FMI studyGlobal Radiotherapy Device Industry Expects to Reach US$ 12,895.19 Million with 6.6% CAGR by 2033 | FMI study
fmiblog.com - April 2 at 3:39 PM
Baxter International lands key FDA clearance for infusion pumpBaxter International lands key FDA clearance for infusion pump
chicagobusiness.com - April 1 at 4:57 PM
Govt Confirms Outbreak of Infectious Disease Amid Covid-19 Fears; Gives Prevention TipsGovt Confirms Outbreak of Infectious Disease Amid Covid-19 Fears; Gives Prevention Tips
msn.com - March 28 at 8:17 PM
Robots in Healthcare Market Future Looks Bright for Market Size with Soaring ProjectionsRobots in Healthcare Market Future Looks Bright for Market Size with Soaring Projections
taiwannews.com.tw - March 28 at 8:44 AM
Radiotherapy Market Will Increase USD 32.6 Billion By 2033 And Has Guessed Around 5.9% CAGRRadiotherapy Market Will Increase USD 32.6 Billion By 2033 And Has Guessed Around 5.9% CAGR
pharmiweb.com - March 25 at 8:52 AM
Kahlert Foundation donates $2.5M to Carroll Hospital for advanced cancer-fighting technologyKahlert Foundation donates $2.5M to Carroll Hospital for advanced cancer-fighting technology
thedailyrecord.com - March 20 at 1:36 PM
Cellino Announces Ed Tekeian as Senior Vice President of EngineeringCellino Announces Ed Tekeian as Senior Vice President of Engineering
finance.yahoo.com - March 18 at 6:19 PM
Global Oncologists Market Report 2024: Precision Medicine and Therapeutic Advancements Drive Expansion to $22.72 Billion by 2028Global Oncologists Market Report 2024: Precision Medicine and Therapeutic Advancements Drive Expansion to $22.72 Billion by 2028
finance.yahoo.com - March 13 at 2:25 PM
Q&A: Chemoradiation With Radiotherapy Improves NSCLC OutcomesQ&A: Chemoradiation With Radiotherapy Improves NSCLC Outcomes
physiciansweekly.com - March 13 at 12:26 AM
Driving becoming increasingly unaffordable in NSW, with regional and low-income communities struggling mostDriving becoming increasingly unaffordable in NSW, with regional and low-income communities struggling most
msn.com - March 11 at 3:07 PM
Forecasted Expansion: Interventional Oncology Ablation Market Expected to Grow at 8.9% CAGRForecasted Expansion: Interventional Oncology Ablation Market Expected to Grow at 8.9% CAGR
pharmiweb.com - March 11 at 3:07 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Bolt Biotherapeutics logo

Bolt Biotherapeutics

NASDAQ:BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Canada Zinc Metals

CVE:CZX
Canada Zinc Metals Corp. explores for and evaluates mineral resource properties in Canada. The company primarily explores for zinc-lead-silver base metals deposits. Its flagship property is the Akie property that consists of 46 mineral claims, which cover approximately 116 square kilometers, located in the Paleozoic Selwyn Basin, British Columbia. The company was formerly known as Mantle Resources Inc. and changed its name to Canada Zinc Metals Corp. in September 2008. Canada Zinc Metals Corp. was incorporated in 1988 and is headquartered in Vancouver, Canada.
First Capital Realty logo

First Capital Realty

TSE:FCR
Varian Medical Systems logo

Varian Medical Systems

NYSE:VAR
Varian Medical Systems, Inc. designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. It operates through Oncology Systems and Proton Solutions segments. The Oncology Systems segment offers hardware and software products for treating cancer with radiotherapy, fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, artificial intelligence based adaptive radiotherapy, and brachytherapy, as well as quality assurance equipment. Its products include linear accelerators, brachytherapy afterloaders, treatment accessories, and quality assurance software; and information management, treatment planning, image processing, clinical knowledge exchange, patient care management, decision-making support, and practice management software. This segment serves university research and community hospitals, private and governmental institutions, healthcare agencies, physicians' offices, medical oncology practices, radiotherapy centers, and cancer care clinics. The Proton Solutions segment designs, develops, manufactures, sells, and services products and systems for delivering proton therapy for the treatment of cancer. The company has a strategic agreement with McKesson Corp. to supply treatment delivery systems and planning, services, and radiotherapy information system solutions to its U.S. Oncology Network and Vantage Oncology affiliated sites of care; and a strategic partnership with Siemens AG to represent Siemens diagnostic imaging products to radiation oncology clinics in the United States and other select markets. Varian Medical Systems, Inc. was formerly known as Varian Associates, Inc. and changed its name to Varian Medical Systems, Inc. in April 1999. The company was founded in 1948 and is headquartered in Palo Alto, California.